A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

A. W. Tolcher, D. I. Quinn, A. Ferrari, Frederick R Ahmann, G. Giaccone, T. Drake, A. Keating, J. S. De Bono

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background: YM155, a small-molecule survivin suppressor, showed modest single-agent activity in a phase I study of heavily pretreated patients. This study was conducted to determine the activity of YM155 in patients with castration-resistant prostate cancer (CRPC) who received prior taxane therapy. Patients and methods: Patients received 4.8 mg/m. 2/day of YM155 over 168-h continuous i.v. infusion every 3 weeks. Study end points included prostate-specific antigen (PSA) response, objective tumor response, safety, progression-free survival (PFS) and overall survival (OS). Results: Thirty-five patients were enrolled. Two of 32 (6.2%) assessable patients had a PSA response and 2 additional patients had PSA decrements >50% but not confirmed. One of 16 (6.2%) patients also had a partial response per RECIST V1. Median PFS and OS were 3.1 and 11.2 months, respectively. The most common adverse events were fatigue (63%), nausea (40%), anorexia (31%), constipation (31%), fever (26%) and vomiting (26%). Conclusions: YM155 has modest activity in taxane-pretreated CRPC with 25% of patients having prolonged stable disease (≥18 weeks). The regimen appears to be well tolerated. Based on the mechanism of action and preclinical evidence of synergy with docetaxel (Taxotere), YM155 combined with docetaxel is being evaluated in patients with CRPC.

Original languageEnglish (US)
Pages (from-to)968-973
Number of pages6
JournalAnnals of Oncology
Volume23
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Castration
Prostatic Neoplasms
docetaxel
Prostate-Specific Antigen
Disease-Free Survival
taxane
Survival
Anorexia
Constipation
Nausea
Vomiting
Fatigue
Fever
Safety

Keywords

  • Apoptosis
  • Prostate cancer
  • Survivin
  • YM155

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. / Tolcher, A. W.; Quinn, D. I.; Ferrari, A.; Ahmann, Frederick R; Giaccone, G.; Drake, T.; Keating, A.; De Bono, J. S.

In: Annals of Oncology, Vol. 23, No. 4, 04.2012, p. 968-973.

Research output: Contribution to journalArticle

Tolcher, A. W. ; Quinn, D. I. ; Ferrari, A. ; Ahmann, Frederick R ; Giaccone, G. ; Drake, T. ; Keating, A. ; De Bono, J. S. / A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. In: Annals of Oncology. 2012 ; Vol. 23, No. 4. pp. 968-973.
@article{33d2846e28ab4b50b8e3ec42b06b6546,
title = "A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer",
abstract = "Background: YM155, a small-molecule survivin suppressor, showed modest single-agent activity in a phase I study of heavily pretreated patients. This study was conducted to determine the activity of YM155 in patients with castration-resistant prostate cancer (CRPC) who received prior taxane therapy. Patients and methods: Patients received 4.8 mg/m. 2/day of YM155 over 168-h continuous i.v. infusion every 3 weeks. Study end points included prostate-specific antigen (PSA) response, objective tumor response, safety, progression-free survival (PFS) and overall survival (OS). Results: Thirty-five patients were enrolled. Two of 32 (6.2{\%}) assessable patients had a PSA response and 2 additional patients had PSA decrements >50{\%} but not confirmed. One of 16 (6.2{\%}) patients also had a partial response per RECIST V1. Median PFS and OS were 3.1 and 11.2 months, respectively. The most common adverse events were fatigue (63{\%}), nausea (40{\%}), anorexia (31{\%}), constipation (31{\%}), fever (26{\%}) and vomiting (26{\%}). Conclusions: YM155 has modest activity in taxane-pretreated CRPC with 25{\%} of patients having prolonged stable disease (≥18 weeks). The regimen appears to be well tolerated. Based on the mechanism of action and preclinical evidence of synergy with docetaxel (Taxotere), YM155 combined with docetaxel is being evaluated in patients with CRPC.",
keywords = "Apoptosis, Prostate cancer, Survivin, YM155",
author = "Tolcher, {A. W.} and Quinn, {D. I.} and A. Ferrari and Ahmann, {Frederick R} and G. Giaccone and T. Drake and A. Keating and {De Bono}, {J. S.}",
year = "2012",
month = "4",
doi = "10.1093/annonc/mdr353",
language = "English (US)",
volume = "23",
pages = "968--973",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

AU - Tolcher, A. W.

AU - Quinn, D. I.

AU - Ferrari, A.

AU - Ahmann, Frederick R

AU - Giaccone, G.

AU - Drake, T.

AU - Keating, A.

AU - De Bono, J. S.

PY - 2012/4

Y1 - 2012/4

N2 - Background: YM155, a small-molecule survivin suppressor, showed modest single-agent activity in a phase I study of heavily pretreated patients. This study was conducted to determine the activity of YM155 in patients with castration-resistant prostate cancer (CRPC) who received prior taxane therapy. Patients and methods: Patients received 4.8 mg/m. 2/day of YM155 over 168-h continuous i.v. infusion every 3 weeks. Study end points included prostate-specific antigen (PSA) response, objective tumor response, safety, progression-free survival (PFS) and overall survival (OS). Results: Thirty-five patients were enrolled. Two of 32 (6.2%) assessable patients had a PSA response and 2 additional patients had PSA decrements >50% but not confirmed. One of 16 (6.2%) patients also had a partial response per RECIST V1. Median PFS and OS were 3.1 and 11.2 months, respectively. The most common adverse events were fatigue (63%), nausea (40%), anorexia (31%), constipation (31%), fever (26%) and vomiting (26%). Conclusions: YM155 has modest activity in taxane-pretreated CRPC with 25% of patients having prolonged stable disease (≥18 weeks). The regimen appears to be well tolerated. Based on the mechanism of action and preclinical evidence of synergy with docetaxel (Taxotere), YM155 combined with docetaxel is being evaluated in patients with CRPC.

AB - Background: YM155, a small-molecule survivin suppressor, showed modest single-agent activity in a phase I study of heavily pretreated patients. This study was conducted to determine the activity of YM155 in patients with castration-resistant prostate cancer (CRPC) who received prior taxane therapy. Patients and methods: Patients received 4.8 mg/m. 2/day of YM155 over 168-h continuous i.v. infusion every 3 weeks. Study end points included prostate-specific antigen (PSA) response, objective tumor response, safety, progression-free survival (PFS) and overall survival (OS). Results: Thirty-five patients were enrolled. Two of 32 (6.2%) assessable patients had a PSA response and 2 additional patients had PSA decrements >50% but not confirmed. One of 16 (6.2%) patients also had a partial response per RECIST V1. Median PFS and OS were 3.1 and 11.2 months, respectively. The most common adverse events were fatigue (63%), nausea (40%), anorexia (31%), constipation (31%), fever (26%) and vomiting (26%). Conclusions: YM155 has modest activity in taxane-pretreated CRPC with 25% of patients having prolonged stable disease (≥18 weeks). The regimen appears to be well tolerated. Based on the mechanism of action and preclinical evidence of synergy with docetaxel (Taxotere), YM155 combined with docetaxel is being evaluated in patients with CRPC.

KW - Apoptosis

KW - Prostate cancer

KW - Survivin

KW - YM155

UR - http://www.scopus.com/inward/record.url?scp=84859422180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859422180&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdr353

DO - 10.1093/annonc/mdr353

M3 - Article

VL - 23

SP - 968

EP - 973

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

ER -